Molecular biology of Barrett's cancer
- PMID: 16997163
- DOI: 10.1016/j.bpg.2006.04.003
Molecular biology of Barrett's cancer
Abstract
Oesophageal adenocarcinoma (OA) remains one of the more deadly forms of gastro-intestinal cancer with a mortality rate exceeding 90%. The incidence of OA remains unabated and has a reported fivefold increase since 1970 [Pera M, Cameron AJ, Trastek VF, Carpenter HA & Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104(2): 510-513]. Gastro-oesophageal reflux disease and its sequelae, Barrett's oesophagus, is one of the principle risk factors in the development of OA, with a 30-fold increased risk in Barrett's patients compared with the general population [Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's-Esophagus) have any real value. Endoscopy 1995; 27(1): 19-26]. OA is thought to be a microcosm of evolution, developing sequentially along the metaplasia-dysplasia-adenocarcinoma sequence. Progression is attributed to a series of genetic and epigenetic events that ultimately allow for clonal selection of Barrett's cells via subversion of intrinsic control mechanisms regulating cellular proliferation and/or apoptosis. This review will describe the current suppositions of the mechanisms behind the selection and subsequent expansion of Barrett's clones, and focus on some of the principle hallmarks associated with this transition.
Similar articles
-
Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.Am J Gastroenterol. 2005 Jun;100(6):1257-64. doi: 10.1111/j.1572-0241.2005.41338.x. Am J Gastroenterol. 2005. PMID: 15929754
-
Barrett's esophagus and risk of esophageal adenocarcinoma.Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Semin Gastrointest Dis. 2003. PMID: 14653412 Review.
-
Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?Gut. 2005 Mar;54 Suppl 1(Suppl 1):i21-6. doi: 10.1136/gut.2004.041558. Gut. 2005. PMID: 15711004 Free PMC article. Review.
-
Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction.Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:48-54; discussion 61-2. doi: 10.1111/j.1365-2036.2004.02138.x. Aliment Pharmacol Ther. 2004. PMID: 15456464 Review.
-
[Carcinogenesis of Barrett's esophagus].Nihon Rinsho. 2005 Aug;63(8):1357-61. Nihon Rinsho. 2005. PMID: 16101221 Review. Japanese.
Cited by
-
Changes in screening, prognosis and therapy for esophageal adenocarcinoma in Barrett's esophagus.Curr Opin Gastroenterol. 2009 Jul;25(4):358-65. doi: 10.1097/MOG.0b013e32832c148f. Curr Opin Gastroenterol. 2009. PMID: 19461512 Free PMC article. Review.
-
Role of Toll-like receptors in gastrointestinal malignancies.Oncogene. 2008 Jan 7;27(2):234-43. doi: 10.1038/sj.onc.1210908. Oncogene. 2008. PMID: 18176605 Free PMC article. Review.
-
Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.Br J Cancer. 2015 Nov 3;113(9):1332-42. doi: 10.1038/bjc.2015.350. Epub 2015 Oct 13. Br J Cancer. 2015. PMID: 26461057 Free PMC article.
-
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.Cancer Res. 2008 Apr 15;68(8):2632-40. doi: 10.1158/0008-5472.CAN-07-5460. Cancer Res. 2008. PMID: 18413730 Free PMC article.
-
MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma.J Mol Med (Berl). 2012 Dec;90(12):1449-58. doi: 10.1007/s00109-012-0924-x. Epub 2012 Jun 17. J Mol Med (Berl). 2012. PMID: 22706599
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials